FGC
BMRN icon

Financial Gravity Companies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Gravity Companies’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$206K Buy
+2,087
New +$199K 0.19% 122
2018
Q1 		$195K Buy
2,367
+1,122
+90% +$96.3K 0.2% 96
2017
Q4 		$112K Buy
+1,245
New +$108K 0.13% 160

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Gravity Companies's BMRN Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2018: 2,087 shares worth $206K. The stake represents 0.19% of the portfolio and ranks #122 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in BMRN as recently as Q1 2018.

Financial Gravity Companies first reported a position in BMRN in Q4 2017 and has held it in 3 quarters since. 472 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • Financial Gravity Companies held 2,087 shares of BioMarin Pharmaceuticals worth $206K as of Q4 2018.
  • BioMarin Pharmaceuticals was a new Financial Gravity Companies position in Q4 2018.
  • BioMarin Pharmaceuticals made up 0.19% of Financial Gravity Companies's portfolio in Q4 2018, its #122 holding.
  • Financial Gravity Companies first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • 472 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.